Europe approves HMO mix for infant formula
The 6’-SL HMO from Chr. Hansen has been approved for highest use levels in infant formula and follow-on formula in Europe. The HMO 6’-Sialyllactose sodium salt, marketed under the trademark MyOli 6’-SL HMO, is now authorised for the EU market under proprietary protection for five years. The EU authorisation includes the highest use level for 6’-SL in infant formula and follow-on-formula (0.70 g/L) in the EU.
The ingredient may reduce the risk of adhesion of harmful bacteria and proteins during infant brain development by supplying sialic acid, an essential building block for neurons.
Chr. Hansen now has EU authorisation for all five HMOs in its MyOli 5 HMO Mix, which contains 2’-FL, 3-FL, LNT, 3’-SL and 6’-SL.
Jesper Sig Mathiasen, Chr. Hansen HMO senior vice president, said the company can now supply the five HMOs and bring infant nutrition solutions closer to breast milk.
HMOs are the third most abundant solid component of breast milk and are known in many different variations. The benefits stem from the structural diversity of HMOs.
Cocoa-free ingredient supplier scales up production
An Italian foodtech company has raised funding to help it expand and scale production of its...
From wheat waste to functional ingredient for future foods
Researchers have transformed wheat bran into hydrogels that could potentially be used to...
€13.4m funding for cellulose alternative to titanium dioxide
Inter IKEA Group has backed a €13.4m Series A for Swiss biomaterials company Seprify, which...
